Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Janssen (J&J Innovative Medicine)

Status

Conditions: Multiple Myeloma

Treatments: Drug: Teclistamab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05161598

CR108846

64007957PTL4001 (Other Identifier)

Details and patient eligibility

About

Teclistamab pre-approval access in relapsed or refractory multiple myeloma.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Must have relapsed/refractory multiple myeloma (RRMM) and have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care (example. proteasome inhibitors [PIs], immunomodulatory imide drugs [IMIDs], anti CD38 monoclonal antibodies [mAbs] and therapies targeting Exportin 1 [XPO1] and B cell maturation antigen [BCMA]). Must not be eligible for a clinical trial with teclistamab or other medicines in this setting